Clinical Trial Update: Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating cetuximab, cisplatin, and BYL719 for HPV-associated oropharyngeal squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-associated Oropharyngeal Squamous Cell Carcinoma
• Oropharyngeal Cancer
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• BYL719 (alpelisib)
• CISPLATIN (cisplatin)
• Cetuximab (cetuximab)

Snippet

Sponsor: Julie E. Bauman, MD, MPH | Conditions: Carcinoma, Squamous, Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN